A Randomized Controlled Trial Assessing the Efficacy and Safety Profile of Oral Ziliv Among Patients with Hepatic Disease Attending the Gastrointestinal Clinic of the Lagos University Teaching Hospital, Idi-Araba

INTERVENTION: Cases CONTROL CONDITION: ; Digestive System ; HEPATOLOGY‐LIVER HEALTH Digestive System HEPATOLOGY‐LIVER HEALTH PRIMARY OUTCOME: The proportion of patients with greater than or equal to 50 percent reduction of ALT. Overall improvement in well‐being after completion of trial. SECONDARY OUTCOME: Proportion with reduced liver enzymes ALT, AST, ALP and bilirubin from the baseline. INCLUSION CRITERIA: 1. All consenting adults (male or female) subjects aged 18years and above. 2. All subjects with elevated alanine aminotransferase (ALT) enzyme levels of at ;least 1.5 times upper limit normal.